CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Fenofibratedrug
Likely dose
Fenofibrate 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03829514
NCT03829514Phase 4Completed
CompareCT.gov

Fenofibrate in Type 2 Diabetes- Novel Biomarkers and Mechanisms

Medical University of South Carolina·interventional·Posted Feb 4, 2019·Updated Oct 24, 2023

In Brief

A Phase 4 clinical trial evaluating Fenofibrate for Diabetes Mellitus, Type II. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Diabetic complications affecting the eyes, kidneys, and nerves are difficult to arrest once in progress. Recent evidence that fenofibrate confers a robust yet unexpected benefit in diabetic retinopathy offers an important translational research opportunity. The investigator's global proteomic study will provide new clues as to how fenofibrate protects vulnerable tissues, and will spur discovery of targets for new therapeutic interventions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type II
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedFeb 4, 2019
Enrollment StartFeb 4, 2019
Primary CompletionMar 4, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.4 years ago

Interventions

Fenofibratedrug

40 patients (20 males and 20 females) aged 18-70 years, with type 2 diabetes and triglycerides \>150 mg/dL will be recruited. They will have a physical exam and blood draw at visit 1. Participants will receive 160 mg fenofibrate to be taken orally daily for six weeks. They will return for a second visit after 6 weeks and have blood draw as follow up.